ZA200901680B - Recombinant human interferon-like proteins - Google Patents

Recombinant human interferon-like proteins

Info

Publication number
ZA200901680B
ZA200901680B ZA200901680A ZA200901680A ZA200901680B ZA 200901680 B ZA200901680 B ZA 200901680B ZA 200901680 A ZA200901680 A ZA 200901680A ZA 200901680 A ZA200901680 A ZA 200901680A ZA 200901680 B ZA200901680 B ZA 200901680B
Authority
ZA
South Africa
Prior art keywords
proteins
recombinant human
human interferon
interferon
recombinant
Prior art date
Application number
ZA200901680A
Other languages
English (en)
Inventor
Haitao Wang
Chunsheng Mao
Jizhi Li
Ling Wang
Yong Du
Lkongbin Liu
Jing Xu
Rui Zhang
Original Assignee
Novagen Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagen Holding Corp filed Critical Novagen Holding Corp
Publication of ZA200901680B publication Critical patent/ZA200901680B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
ZA200901680A 2007-06-18 2009-03-10 Recombinant human interferon-like proteins ZA200901680B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/764,786 US7625555B2 (en) 2007-06-18 2007-06-18 Recombinant human interferon-like proteins

Publications (1)

Publication Number Publication Date
ZA200901680B true ZA200901680B (en) 2010-03-31

Family

ID=40132903

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200901680A ZA200901680B (en) 2007-06-18 2009-03-10 Recombinant human interferon-like proteins

Country Status (21)

Country Link
US (8) US7625555B2 (de)
EP (3) EP3133161A1 (de)
JP (3) JP5439189B2 (de)
KR (2) KR20130027043A (de)
CN (3) CN101432428B (de)
AU (1) AU2007355415B2 (de)
BR (1) BRPI0716948B1 (de)
CA (1) CA2692358C (de)
DK (2) DK2465935T3 (de)
ES (2) ES2524251T3 (de)
HK (2) HK1129128A1 (de)
IL (1) IL196673A (de)
MX (1) MX2009001366A (de)
MY (1) MY167485A (de)
NZ (1) NZ574306A (de)
PL (2) PL2078082T3 (de)
PT (2) PT2465935T (de)
RU (1) RU2469091C2 (de)
TW (1) TWI375716B (de)
WO (1) WO2008154719A1 (de)
ZA (1) ZA200901680B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
RU2573909C2 (ru) 2010-03-04 2016-01-27 Пфенекс Инк. Способ получения растворимого рекомбинантного белка интерферона без денатурирования
AU2014322046B2 (en) * 2013-09-20 2021-02-04 Daiichi Sankyo Company, Limited Complex containing oligonucleotide having immunopotentiating activity and use thereof
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
WO2016009451A2 (en) * 2014-07-14 2016-01-21 Gennova Biopharmaceuticals Limited A novel process for purification of rhu-gcsf
NZ751483A (en) * 2016-09-01 2022-07-01 Proqr Therapeutics Ii Bv Chemically modified single-stranded rna-editing oligonucleotides
WO2018101151A1 (ja) * 2016-12-02 2018-06-07 興人ライフサイエンス株式会社 リボース含有酵母調味料
US10780931B2 (en) * 2018-05-21 2020-09-22 Ronald Siwicki Kickstand assembly
CN109627343A (zh) * 2018-12-27 2019-04-16 北京美福源生物医药科技有限公司 长效细胞因子基因衍生物融合蛋白
CN113289006A (zh) * 2020-02-24 2021-08-24 杰华生物技术(青岛)有限公司 一种重组细胞因子基因衍生蛋白或其片段的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US369922A (en) 1887-09-13 Jacket for steam-cylinders
US2004200A (en) * 1931-10-02 1935-06-11 Union Switch & Signal Co Lamp socket adapter
US3699222A (en) * 1958-03-11 1972-10-17 Nat Res Dev Production of viral interfering substances
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
DE3685996T2 (de) * 1985-06-11 1993-01-14 Ciba Geigy Ag Hybrid-interferone.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0730470B1 (de) * 1993-11-10 2002-03-27 Enzon, Inc. Verbesserte interferon-polymerkonjugate
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
FR2741892B1 (fr) * 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
EP1037995A1 (de) * 1997-12-08 2000-09-27 Genentech, Inc. Menschliches interferon-epsilon: ein typ 1 interferon
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
CN1501815A (zh) 1999-08-27 2004-06-02 新的干扰素β-样分子
US7431921B2 (en) * 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CN1451045A (zh) * 1999-10-07 2003-10-22 马克西根公司 IFN－α同系物
US20040002474A1 (en) * 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
JP2003513681A (ja) 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
EP1275713A4 (de) 2000-03-31 2004-06-30 Mochida Pharm Co Ltd Tlr/cd14-bindender hemmstoff
AU2002212107A1 (en) 2000-11-02 2002-05-15 Maxygen Aps New multimeric interferon beta polypeptides
WO2002036627A2 (en) 2000-11-03 2002-05-10 Pbl Biomedical Laboratories Interferons, uses and compositions related thereto
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
MXPA03009082A (es) 2001-04-06 2004-11-22 Maxygen Holdings Ltd Variantes polipeptidicas de interferon gamma.
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
US6958388B2 (en) * 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
FR2825102B1 (fr) * 2001-05-23 2003-08-29 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
JP2004522803A (ja) 2001-06-29 2004-07-29 マキシゲン・エイピーエス インターフェロン製剤
CN1431018A (zh) 2002-01-10 2003-07-23 北京东康龙病毒生物技术工程研究中心 抗HSV感染和镇痛的人甲硫氨酸脑啡肽干扰素α－m融合蛋白制剂
KR20040104504A (ko) 2002-03-12 2004-12-10 맥시겐 에이피에스 스트로크의 치료를 위한 인터페론 베타-유사 분자
US7524931B2 (en) 2002-07-03 2009-04-28 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
NZ540043A (en) 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates
WO2005023290A2 (en) * 2003-05-23 2005-03-17 Pestka Biomedical Laboratories, Inc. Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
WO2007044083A2 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins

Also Published As

Publication number Publication date
EP2078082A4 (de) 2009-12-16
EP2465935A2 (de) 2012-06-20
US7868151B2 (en) 2011-01-11
AU2007355415A1 (en) 2008-12-24
ES2586398T3 (es) 2016-10-14
MX2009001366A (es) 2009-04-17
IL196673A0 (en) 2011-08-01
EP2465935B1 (de) 2016-05-18
KR20100033468A (ko) 2010-03-30
BRPI0716948A2 (pt) 2013-02-19
CN102250918A (zh) 2011-11-23
EP2465935A3 (de) 2012-08-15
JP6099095B2 (ja) 2017-03-22
US9234022B2 (en) 2016-01-12
JP5439189B2 (ja) 2014-03-12
RU2469091C2 (ru) 2012-12-10
CA2692358A1 (en) 2008-12-24
US20100129904A1 (en) 2010-05-27
US9982028B2 (en) 2018-05-29
US7867482B2 (en) 2011-01-11
US20200369741A1 (en) 2020-11-26
AU2007355415B2 (en) 2012-07-26
US20100099612A1 (en) 2010-04-22
PT2078082E (pt) 2014-11-27
US20130189226A1 (en) 2013-07-25
CN103483443A (zh) 2014-01-01
MY167485A (en) 2018-08-30
US7625555B2 (en) 2009-12-01
PT2465935T (pt) 2016-08-05
JP2010515466A (ja) 2010-05-13
JP2016117753A (ja) 2016-06-30
KR101384307B1 (ko) 2014-05-21
DK2078082T3 (en) 2014-12-01
KR20130027043A (ko) 2013-03-14
HK1171048A1 (zh) 2013-03-15
CN101432428B (zh) 2013-06-19
DK2465935T3 (en) 2016-08-22
TWI375716B (en) 2012-11-01
IL196673A (en) 2015-08-31
US20190077843A1 (en) 2019-03-14
US20080312148A1 (en) 2008-12-18
JP2014036657A (ja) 2014-02-27
US20100303759A1 (en) 2010-12-02
US8425895B2 (en) 2013-04-23
PL2078082T3 (pl) 2015-02-27
CA2692358C (en) 2012-11-20
US10538565B2 (en) 2020-01-21
WO2008154719A1 (en) 2008-12-24
RU2009104749A (ru) 2010-11-20
NZ574306A (en) 2012-07-27
US20170015723A1 (en) 2017-01-19
EP3133161A1 (de) 2017-02-22
EP2078082B1 (de) 2014-08-20
CN101432428A (zh) 2009-05-13
HK1129128A1 (en) 2009-11-20
PL2465935T3 (pl) 2017-08-31
ES2524251T3 (es) 2014-12-04
EP2078082A1 (de) 2009-07-15
TW200900504A (en) 2009-01-01
BRPI0716948B1 (pt) 2022-04-05

Similar Documents

Publication Publication Date Title
HK1171048A1 (zh) 重組人干擾素樣蛋白
SI3118220T1 (sl) Protein
EP2173377A4 (de) Antikörper-endostatin-fusionsprotein und seine varianten
EP2172198A4 (de) P27-protein-induktor
GB0611116D0 (en) Proteins
IL203221A (en) Bioactive peptides and antibodies
GB0601976D0 (en) Proteins
HK1124343A1 (en) Truncated human papillomavirus type 6 l1 proteins
EP2147926A4 (de) Trunkierte l1-proteine des humanen papillomavirus typ 18
GB0620735D0 (en) Proteins
GB0725201D0 (en) Peptide fusion proteins
GB0719231D0 (en) Protein
EP2024516A4 (de) Perforin-2-proteine
IL206334A0 (en) Sarp-i fusion proteins and their use
EP2244725A4 (de) Neuartige peptide und proteine sowie verwendungen davon
HK1146905A1 (en) Reverse protein
GB0720563D0 (en) Protein
GB0614682D0 (en) Proteins
GB0612623D0 (en) Proteins
GB0620304D0 (en) Protein
GB0700759D0 (en) Novel fusion protein
GB0511861D0 (en) Proteins
GB0422110D0 (en) Recombinant proteins
GB0713302D0 (en) Protein
GB0719236D0 (en) Protein